Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | AKT1 | P31749 | 3/20 | 0.75 |
| ▸ | CTH | P32929 | 1/20 | 0.75 |
| ▸ | TDP2 | O95551 | 1/20 | 0.52 |
| ▸ | TCF4 | P15884 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | STAT3 | P40763 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nanaomycin SCHEMBL20473784 | 1.00 | HSP90AA1 (1.00) | HSP90AA1DNMT3BPAX8AKT1CTH | |
| Nanaomycin SCHEMBL30778402 | 1.00 | HSP90AA1 (1.00) | HSP90AA1DNMT3BPAX8AKT1CTH | |
| Nanaomycin SCHEMBL30861963 | 1.00 | HSP90AA1 (1.00) | HSP90AA1DNMT3BPAX8AKT1CTH | |
| Nanaomycin SCHEMBL18567076 | 1.00 | HSP90AA1 (1.00) | HSP90AA1DNMT3BPAX8AKT1CTH | |
| SCHEMBL30193239 | 0.90 | DNMT3B (0.82) | HSP90AA1DNMT3BPAX8AKT1CTH | |
| SCHEMBL29927569 | 0.88 | DNMT3B (0.78) | HSP90AA1DNMT3BPAX8AKT1CTH | |
| SCHEMBL28398864 | 0.87 | DNMT3B (0.77) | HSP90AA1DNMT3BPAX8AKT1CTH | |
| SCHEMBL20144857 | 0.86 | DNMT3B (0.75) | HSP90AA1DNMT3BPAX8AKT1CTH | |
| SCHEMBL1177648 | 0.80 | DNMT3B (0.66) | HSP90AA1DNMT3BPAX8AKT1CTH | |
| SCHEMBL20442857 | 0.80 | DNMT3B (0.66) | HSP90AA1DNMT3BPAX8AKT1CTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| WO-2025063844-A1 | ENHANCEMENT OF T CELL MEDIATED THERAPIES WITH A DNA HYPOMETHYLATING AGENT AND A SUMOYLATION INHIBITOR | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-03-27 | — | — | WO | claimed |
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. | 2025-01-02 | — | — | US | claimed |
| US-20240269157-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2024-08-15 | — | — | US | claimed |
| EP-4404969-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| WO-2023147573-A2 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) | 2023-08-03 | — | — | WO | claimed |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2023-07-13 | — | — | US | claimed |
| EP-4164655-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GlycoMimetics, Inc. (US) | 2023-04-19 | — | — | EP | claimed |
| EP-4157315-A1 | COMBINATION THERAPIES COMPRISING A HYPOMETHYLATION AGENT FOR TREATING CANCER | ALX Oncology Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| WO-2023049862-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-104278008-A | Method, kit and applications of preparing pluripotent stem cells through small-molecule compound treatment | SCIENCE AND TECHNOLOGY DEV PEKING UNIVERSITY OFF OF | 2015-01-14 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-6372772-B1 | ENZYME INHIBITORS FOR REDUCTASE SYSTEMS IN CELLS | PROLX PHARMACEUTICALS CORPORATION | 2002-04-16 | — | — | US | claimed |
| WO-2000006088-A2 | INHIBITORS OF REDOX SIGNALING AND METHODS OF USING SAME | PROLX PHARMACEUTICALS, LP (US) | 2000-02-10 | — | — | WO | claimed |
| US-4324728-A | QUINONE-LIKE ANTIBIOTICS | THE KITASATO INSTITUTE (JP) | 1982-04-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | SELE, SELPLG, MCL1 | HSP90AA1 661/4885DNMT3B 420/4885PAX8 3304/4885 |
| US-20240269157-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | SELE, SELPLG, MCL1 | HSP90AA1 661/4885DNMT3B 420/4885PAX8 3304/4885 |
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | NFATC1, MKI67, ICOS | HSP90AA1 1295/4885DNMT3B 56/4885PAX8 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.